𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas

✍ Scribed by Asunción Esteve; Ghyslaine Martel-Planche; Bakary S. Sylla; Monica Hollstein; Pierre Hainaut; Ruggero Montesano

Publisher
John Wiley and Sons
Year
1996
Tongue
French
Weight
515 KB
Volume
66
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Mutational analysis of the pl6ICDKN2 gene was conducted by direct sequencing of the whole coding sequence (exom 1-3 and flanking splicing sites) in 21 esophageal squamous-cell carcinomas and 3 adenocarcinomas from a high-incidence area of Italy. Two inactivating mutations were found in exon I of the gene (both in squamous-cell carcinoma), whereas no mutations were detected in exon 2, where most of the sequence changes reported so far have been located, or in exon 3. Southern blot analysis of exon 2 in this set of samples and in a complementary set of I2 tumor samples from France did not show homozygous deletions or detectable gene rearrangements. Thus, pl6l CDKNl gene alterations do not appear to play a major role in the group of patients examined.

📜 SIMILAR VOLUMES

Low frequency of CDKN2 mutation in endom
Low frequency of CDKN2 mutation in endometrial carcinomas
✍ Stacia L. Peiffer; Detlef Bartsch; Alison J. Whelan; David G. Mutch; Thomas J. H 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

## Abstract The __CDKN2__ gene on chromosome 9p21 encodes the p16 inhibitor of cyclin D/cyclin‐dependent kinase 4 complexes. Mutations and deletions of __CDKN2__ have been frequently identified in cell lines, whereas most primary tumors have demonstrated a lower frequency of alteration. To assess t

Loss of heterozygosity on chromosome 9 a
Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers
✍ Françoise Muzeau; Jean François Fléjou; Gilles Thomas; Richard Hamelin 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 131 KB 👁 1 views

Loss of heterozygosity on chromosome 9 has been reported in a variety of human cancers. The cyclin-dependent kinase inhibitor p16 gene, mapped on chromosome 9p21, is presumed to be the tumor-suppressor gene localized in this chromosome. The aim of our study was to determine, in 26 Barrett's adenocar

p53 and p16/CDKN2 gene mutations in esop
p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa
✍ Wedaad Gamieldien; Thomas C. Victor; David Mugwanya; Andrew Stepien; Wentzel C. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 98 KB 👁 1 views

Squamous cell carcinoma of the esophagus has an uneven geographic distribution, with a high incidence in the Transkei region of Eastern Cape Province, South Africa. The precise molecular events associated with tumorigenesis of esophageal cancer in this region have not been characterized. DNA from hu

Low frequency of BRAF and CDKN2A mutatio
Low frequency of BRAF and CDKN2A mutations in endometrial cancer
✍ Helga B. Salvesen; Rajiv Kumar; Ingunn Stefansson; Sabrina Angelini; Nicola MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 196 KB 👁 1 views

## Abstract Several pathways have been implicated in the pathogenesis of endometrial carcinoma. Based on recent reports, __BRAF__ mutations provide an alternative route for activation of the RAS signalling pathway. The __CDKN2A (p16)__ tumour suppressor gene is also altered in several tumour types.

Frequency of mutation and deletion of th
Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population
✍ K Biden; J Young; R Buttenshaw; J Searle; G Cooksley; D B Xu; B Leggett 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 476 KB

The tumor suppressor gene CDKN2A (MTS1/p16), located on chromosome 9p21, is inactivated in a variety of tumors including melanomas and tumors of the biliary tract, pancreas, and stomach. The aim of the present study was to determine whether this gene is inactivated in hepatocellular carcinoma (HCC).